生命科学资讯

Patient dies in MacroGenics' cancer study, FDA puts trial on hold

Beam Therapeutics' new PKU program; Protara's bladder cancer data

Abcuro drug fails muscle weakness trial, development to continue

Immedica wins accelerated approval for once-rejected rare disease drug

New biotech Slate Medicines raises $130M for migraine drug from China

Novo Nordisk’s triple-G is competitive with Lilly in obesity, but likely to be second to market

Pfizer buys China rights to Sciwind’s approved GLP-1 drug in metabolic push

Hims reports 2025 earnings, shares details on GLP-1 pill decisions

Astellas pays $240M cash for Vir's prostate cancer drug

QurAlis' ALS drug sees early positive signal, but questions remain

Swiss Rockets buys MGI subsidiary Complete Genomics after Biosecure Act

Fortress to sell priority review voucher for $205M

FDA unveils long-awaited guidance on new pathway for individualized therapies

Flagship's Generate targets $2B+ valuation with Nasdaq IPO

AbbVie budgets $380M for obesity and neuroscience API facilities in Chicago

Frontier, Harbour do licensing deals with GSK, Solstice

A federal experiment opens up a new market for digital health — if it works